Differential apoptotic behaviors of c-myc, N-myc, and L-myc oncoproteins

Cell Growth and Differentiation

Volumn 9, Issue 9, 1998, Pages 731-741

  Nesbit, Chadd E ^a   Grove, Linette E ^a   Yin, Xiaoying ^a   Prochownik, Edward V ^a,b,c  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC AGENT; INTERLEUKIN 3; ONCOPROTEIN; PROTEIN BCL 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL LINE; CELL PROTECTION; CONTROLLED STUDY; DRUG RESISTANCE; DRUG SENSITIVITY; GENE OVEREXPRESSION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-X PROTEIN; CELL LINE; CULTURE MEDIA; INTERLEUKIN-3; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-MYC;

ANIMALIA;

EID: 0031713989     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Evan, G. I., and Littlewood, T. D. The role of c-myc in growth. Curr. Opin. Genet. Dev., 3: 44-49, 1993.
2. Evan, G., Harrington, E., Fanidi, A., Land, H., Amati, B., and Bennett, M. Integrated control of cell proliferation and cell death by the c-myc oncogene. Phil. Trans. R. Soc. Lond. B, 345: 269-275, 1994.
3. Packham, G., and Cleveland, J. L. c-myc and apoptosis. Biochim. Biophys. Acta, 1242: 11-28, 1995.
4. Evan, G. I., Wylie, A. H., Gilbert, C. S., Littlewood, T. D., Land, H., Brooks, M., Waters, C. M., Penn, L. Z., and Hancock, D. C. Induction of apoptosis in fibroblasts by c-myc protein. Cell, 69: 119-128, 1992.
5. Sakamuro, D., Eviner, D., Elliott, K. J., Show, L., White, E., and Prendergast, G. C. c-myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene, 11: 2411-2418, 1995.
6. Askew, D. S., Ashmun, R. A., Simmons, B. C., and Cleveland, J. L. Constitutive c-myc expression in an IL-3 dependent myeloid cell line suppresses cell cycle arrest and induces apoptosis. Oncogene, 6: 1915-1922, 1991.
7. Lotem, J., and Sachs, L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ. 44: 41-47, 1993.
8. Blackwood, E. M., and Eisenman, R. N. Max: a helix-loop-helix-zipper protein that forms a sequence-specific DNA binding complex with myc. Science (Washington DC), 251: 1211-1217, 1991.
9. Amati, B., Littlewood, T. D., Evan, G. I., and Land, H. The c-myc protein induces cell cycle progression and apoptosis through dimerization with Max. EMBO J., 12: 5083-5087, 1993.
10. Hermeking, H., and Eick, D. Mediation of c-myc induced apoptosis by p53. Science (Washington DC), 265: 2091-2093, 1994.
11. Bissonnette, R. P., Echeverri, F., Mahboubi, A., and Green, D. R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature (Lond.), 359: 552-554, 1992.
12. Fanidi, A., Harrington, E. A., and Evan, G. I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature (Lond.), 359: 554-556, 1992.
13. Wagner, A. J., Small, M. B., and Hay, N. myc-mediated apoptosis is blocked by ectopic expression of bcl-2. Mol. Cell. Biol., 13: 2432-4440, 1993.
14. Kohl, N. E., Legouy, E., DePinho, R. A., Nissen, P. D., Smith, R. K., Gee, C. E., and Alt, F. W. Human N-myc is closely related in organization and nucleotide sequence to c-myc. Nature (Lond.), 319: 73-77, 1986.
15. Nau, M. M., Brooks, B. J., Battey, J., Sausville, E., Gazdor, A. F., Kirsch, I. R., McBridge, O. W., Bertness, V., Hollis, G. F., and Minna, J. D. L-myc, a new myc-related gene amplified and expressed in human small cell lung cancer. Nature (Lond.), 318: 69-73, 1985.
16. Stanton, L. W., Schwab, M., and Bishop, J. M. Nucleotide sequence of the human N-myc gene. Proc. Natl. Acad. Sci. USA, 83: 1772-1776, 1986.
17. Prochownik, E. V., and Van Antwerp, M. E. Differential patterns of DNA binding by myc and max proteins. Proc. Natl. Acad. Sci. USA, 90: 960-964, 1993.
18. Ma, A., Moroy, T., Collum, R., Weintraub, H., Alt, F. W., and Blackwell, T. K. DNA-binding by N-and L-myc proteins. Oncogene, 8: 1093-1098, 1993.
19. Birrer, M. J., Segal, S., DeGreve, J. S., Kaye, F., Sausville, E. A., and Minna, J. D. L-myc cooperates with ras to transform primary rat embryo fibroblasts. Mol. Cell. Biol., 8: 2668-2673, 1988.
20. Schwab, M., Varmus, H. E., and Bishop, J. M. Human N-myc gene contributes to neoplastic transformation of mammalian cells in culture. Nature (Lond.), 316: 160-162, 1985.
21. Small, M. B., Hay, N., Schwab, M., and Bishop, J. M. Neoplastic transformation by the human gene N-myc. Mol. Cell. Biol., 7: 1638-1645, 1987.
22. Yancopoulos, G. D., Nissen, P. D., Tesfaye, A., Kohl, N. E., Goldfarb, M. P., and Alt, F. W. N-myc can cooperate with ras to transform normal cells in culture. Proc. Natl. Acad. Sci. USA, 82: 5455-5459, 1985.
23. Zimmerman, K., and Alt, F. W. Expression and function of myc family genes. Crit. Rev. Oncogenes, 2: 75-95, 1990.
24. Barrett, J., Birrer, M. J., Kato, G. J., Dosoka-Akita, H., and Dang, C. V. Activation domains of L-myc and c-myc determine their transforming potencies in rat embryo cells. Mol. Cell. Biol., 12: 3130-3137, 1992.
25. Greenberger, J. S., Sakakeeney, M. A., Humphries, R. K., Eaves, C. J., and Eckner, R. J. Demonstration of permanent factor-dependent multipotential (erythroid/neutrophil/basophil) hematopoietic cell lines. Proc. Natl. Acad. Sci USA, 80: 2931-2935, 1983.
26. Blandino, G., Scardigli, R., Rizzo, M. G., Crescenzi, M., Soddu, S., and Sacchi, A. Wild-type p53 modulates apoptosis of normal, IL-3-deprived, hematopoietic cells. Oncogene, 10: 731-737, 1995.
27. Migliaccio, G., Migliaccio, A. R., Kreider, B. L., Rovera, G., and Adamson, J. W. Selection of lineage-restricted cell lines immortalized at different stages of hematopoietic differentiation from the murine cell line 32D. J. Cell Biol., 109: 833-838, 1989.
28. Valtieri, M., Tweardy, D. J., Caracciolo, D., Johnson, K., Mavilio F., Altmann, S., Santoli, D., and Rovera, G. Regulation of proliferative and differentiative responses in a murine progenitor cell line. J. Immunol., 138: 3829-3835, 1987.
29. Smith, M. J., Charron-Prochownik, D. C., and Prochownik, E. V. The leucine zipper of c-myc is required for inhibition of erythroleukemia differentiation. Mol. Cell. Biol., 10: 5333-5339, 1990.
30. Yu, C-L., Prochownik, E. V., and Jove, R. Proximal promoter region of the junB gene mediates attenuation of serum inducibility in src-transformed cells. Cell Growth Differ., 6: 1513-1521, 1995.
31. Pommier, Y., Leteutre, F., Fesen, M. R., Fujimori, A., Bertrand, R., Solary, E., Kohlhagen, G., and Kohn, K. W. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 12: 530-542, 1994.
32. Ross, W. DNA topoisomerases as targets for cancer therapy. Biochem. Pharmacol., 34: 4191-4195, 1985.
33. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58: 351-375, 1989.
34. Gupta, M., Fujimori, A., and Pommier, Y. Eukaryotic DNA topoisomerases I. Biochim. Biophys. Acta, 1262: 1-14, 1995.
35. Eastman, A. Activation of programmed cell death by anticancer agents: cisplatin as a model system. Cancer Cells, 2: 275-280, 1990.
36. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E., p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
37. Lowe, S. W., Bodis, S., McClatchey, A., Remington, L., Ruley, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
38. L can confer a multidrug resistance phenotype. Blood, 86: 1903-1910, 1995.
39. Walton, M. I., Whysong, D., O'Connor, P. M., Hockenberry, D., Korsmeyer, S. J., and Kohn, K. W. Constitutive expression of human Bcl-2 modulates nitrogen mustard and camptothecin induced apoptosis. Cancer Res., 53: 19853-1861, 1993.
40. Canman, C. E., Gilmer, T., Courts, S. B., and Kastan, M. B. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev., 9: 600-611, 1995.
41. DiLeonardi, A., Linke, S. P., Clarkin, K., and Wahl, G. M. DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in norman human fibroblasts. Genes Dev., 8: 2540-2551, 1994.
42. Murray, A., and Hunt, T. Check points and feedback controls. In: The Cell Cycle: An Introduction, pp. 139-161. New York: W. H. Freeman & Co., 1993.
43. Yount, G. L., Haas-Kogan, D. A., Vidair, C. A., Haas, M., Dewey, W. C., and Israel, M. A. Cell cycle synchrony unmasks the influence of p53 function on radiosensitivity of human glioblastoma cells. Cancer Res., 56: 500-506, 1996.
44. L can inhibit apoptosis in cells that have undergone Fas-induced protease activation. Proc. Natl. Acad. Sci. USA, 94: 3759-3764, 1997.
45. Miyashita, T., and Reed, J. C. bcl-2 gene transfer increases relative resistance of S49.1 and WEHI17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res., 52: 5407-5411, 1997.
46. Reed, J. C. Bcl-2 and the regulation of programmed cell death. J. Cell Biol., 124: 1-6, 1994.
47. Sklar, M. D., and Prochownik, E. V. Modulation of cisplatinum resistance in Friend erythroleukemia cells by c-myc. Cancer Res., 51: 2118-2123, 1991.
48. Eilers, M., Schirm, S., and Bishop, J. M. The myc protein activates transcription of the α-prothymosin gene. EMBO J., 10: 133-141, 1991.
49. Pellegata, N. S., Antoniono, R. J., Redpath, J. L., and Stanbridge, E. J. DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc. Natl. Acad. Sci. USA, 93: 15209-15214, 1996.
50. Cross, S. M., Sanchez, C. A., Morgan, C. A., Schimke, M. K., Ramel, S., Idzerda, R. L., Raskind, W. H., and Reid, B. J. A p53-dependent mouse spindle checkpoint Science (Washington DC), 267: 1353-1356, 1995.
51. Jacks, T., and Weinberg, R. A. Cell cycle control and its watchman. Nature (Lond.), 381: 643-644, 1996.
52. Ko, J., and Prives, C. p53: puzzle and paradigm. Genes Dev., 10: 1054-1072, 1996.
53. Fingert, H. J., Chang, J. D., and Pardee, A. B. Cytotoxic, cell cycle, and chromosomal effects of methylxanthines in human tumor cells treated with alkylating agents. Cancer Res., 46: 2463-2467, 1986.
54. Fingert, H. J., Pu, A. T., Chen, Z., Googe, P. B., Alley, M. C., and Pardee, A. B. In vivo and in vitro enhanced antitumor effects of pentoxifylline in human cancer cells treated with thiotepa. Cancer Res., 48: 4375-4381, 1988.
55. Gottlieb, E., Haffner, R., von Ruden, T., Wagner, E. F., and Oren, M. Down-regulation of wild-type p53 interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J., 13: 1368-1374, 1994.
56. Silva, A., Wyllie, A., and Collins, M. K. L. p53 is not required for regulation of apoptosis or radioprotection by interleukin-3. Blood, 89: 2717-2722, 1997.
57. Yang, E., and Korsmeyer, S. J. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood, 88: 386-401, 1996.
58. Zhang, H., Fan, S., and Prochownik, E. V. Distinct roles for max protein isoforms in proliferation and apoptosis. J. Biol. Chem., 272: 17416-17424, 1997.
59. 2+ mobilization through distinct pathways. EMBO J., 13: 1341-1349, 1994.
60. Clarke, M. F., Kukowska-Latallo, J. F., Westin, E., Smith, M., and Prochownik, E. V. Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol. Cell. Biol., 8: 884-892, 1988.